Sildenafil
Product Images NDC 53002-2719

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 53002-2719). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image (Lbl530022719)

Label Image (Lbl530022719)
FDA Label Image

Figure-10 (Sildenafil Fig 10)

Figure-10 (Sildenafil Fig 10)
FDA Label Image

Figure-11 (Sildenafil Fig 11)

Figure-11 (Sildenafil Fig 11)
FDA Label Image

Fig-12 (Sildenafil Fig 12)

Fig-12 (Sildenafil Fig 12)
FDA Label Image

Fig-6 (Sildenafil Fig 6)

Fig-6 (Sildenafil Fig 6)
FDA Label Image

Fig-8 (Sildenafil Fig 8)

Fig-8 (Sildenafil Fig 8)
This is a chart providing information on the recommended dosage adjustments of various drugs in the presence of interacting drugs. The data is presented in terms of fold change and 90% confidence intervals. Some drugs require a dosage adjustment when co-administered with the interacting drug while others do not. The chart also includes information on the change in relative to interacting drug alone and the effect of certain drug combinations on exercise capacity and PK levels.*
FDA Label Image

Figure-9 (Sildenafil Fig 9)

Figure-9 (Sildenafil Fig 9)
FDA Label Image

Figure-7 (Sildenafil Figure 7)

Figure-7 (Sildenafil Figure 7)
This is a chart that shows the fold change and %0% CI recommendation for interacting drugs. The chart shows that there is no need for dose adjustment for Atorasttn, Astromycn UG, Bosentan, Cimetidine, Evermyel:f, beoanod c, Oral Contraceptives, and Saquinavie. The chart also shows a vertical solid line at x=1, which represents the change relative to Sildenafil alone. The 95% Cl indicates the AUC accumulation ratio from Day 1o Day 7 relative to Sildenafil alone. The chart concludes that there is no benefit on exercise capacity when Sildenafil is added to Bosentan therapy.*
FDA Label Image

Str (Sildenafil Str)

Str (Sildenafil Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.